Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andrivet, P.
Right arrow Articles by Adnot, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andrivet, P.
Right arrow Articles by Adnot, S.
(Chest. 1994;106:118-124.)
© 1994 American College of Chest Physicians

Intravenously Administered Atrial Natriuretic Factor in Patients With COPD

Effects on Ventilation-Perfusion Relationships and Pulmonary Hemodynamics

Pierre Andrivet M.D.1; Pierre-Etienne Chabrier M.D.2; Christian Defouilloy M.D.1; Christian Brun-Buisson M.D.3; and Serge Adnot M.D.1

1 From Laboratoire d'Explorations Fonctionnelles et Unité INSERM U296, Hôpital Henri Mondor, Creteil France
2 From Laboratoire Beaufour, Les Ulis, France
3 From Medical Intensive Care Unit, Hôpital Henri Mondor, Creteil France

The potent pulmonary vasodilating property of atrial natriuretic factor (ANF) may alter gas exchange in patients with COPD. We examined the hemodynamic and gas exchange responses to intravenous infusion of ANF (0.01 and 0.03 ng/min/kg body weight) in eight stable patients with COPD studied during spontaneous breathing, using the inert gas elimination technique. When compared with baseline, ANF infusion was associated with a dose-dependent decrease in pulmonary artery pressure (from 27.3±2.5 to 23.9±1.8 and 20.2±1.7 mm Hg, respectively) and a dose-dependent increase in blood flow perfusing poorly ventilated and unventilated units (VA/Q <0.1: from 5.80±2.05 to 7.25±2.5 and 12.0±5.4 percent of total blood flow, respectively; p=0.02). However, PaO2 remained unchanged (70.2±3.6, 68.1±3.8 65.4±3.5 mm Hg, respectively) because of a significant increase in minute ventilation (VE) from 8.6±0.8 to 9.6±0.8 and 10.3±0.7 L/min (p<0.002). Six additional COPD patients receiving intravenously administered ANF at the same dosages were studied during controlled mechanical ventilation using right heart catheterization. In these patients, pulmonary vasodilation was associated with a significant increase in venous admixture (from 12.7±2.4 to 14.4±2.9 and 17.5±3.5 percent of total blood flow, respectively; p<0.02), and a dose-dependent reduction in arterial PO2 (from 117±17 to 110±15 and 96.4±8.8 mm Hg, respectively; p<0.05). The present results show that ANF infusion is associated with alterations in the VA/Q relationship in patients with COPD. However, a decrease in arterial oxygenation may be prevented by an increase in VE.

Submitted on May 28, 1993
Accepted on November 29, 2007




This article has been cited by other articles:


Home page
 ChestHome page
J. R. Klinger, S. Thaker, J. Houtchens, I. R. Preston, N. S. Hill, and H. W. Farber
Pulmonary hemodynamic responses to brain natriuretic Peptide and sildenafil in patients with pulmonary arterial hypertension.
Chest, February 1, 2006; 129(2): 417 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J.A. Barbera, V.I. Peinado, and S. Santos
Pulmonary hypertension in chronic obstructive pulmonary disease
Eur. Respir. J., May 1, 2003; 21(5): 892 - 905.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. T. Schermuly, N. Weissmann, B. Enke, H. A. Ghofrani, W. G. Forssmann, F. Grimminger, W. Seeger, and D. Walmrath
Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension . Synergism upon Coapplication
Am. J. Respir. Cell Mol. Biol., August 1, 2001; 25(2): 219 - 225.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American College of Chest Physicians.